Transplant Complications Working Party (TCWP)
Type of Stem Cell Treatment:
The primary endpoint of the study was non-relapse mortality at two years after allo-SCT. Overall survival, relapse incidence, chronic (c) GvHD incidence at two years, acute (a) GVHD incidence, non-engraftment at day 30 after allo-SCT were selected as secondary endpoints.
Key inclusion criteria:
Eligibility criteria included patients receiving a first allo-SCT using mobilized peripheral blood (PB) or bone marrow (BM) between 2005 – 2017.
EBMT Study coordinator:
Study coordinator email: